SOURCE: ChromaDex Corporation
IRVINE, CA--(Marketwire - Aug 30, 2012) - ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, has been invited to present at the 2012 Gateway Conference being held on September 6th at the W San Francisco Hotel.
ChromaDex's CEO, Frank Jaksch, is scheduled to present at 1:00 p.m. Pacific Time, with one-on-one meetings held throughout the day. Management will discuss the company's growth prospects driven by its pipeline of proprietary products including its patented pTeroPure® (pterostilbene), which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. Human clinical data for its pTeroPure® study will be presented on September 20, 2012 at the High Blood Pressure Research 2012 Scientific Sessions, sponsored by the American Heart Association's Council for High Blood Pressure Research and Council on Kidney in Cardiovascular Disease.
The presentation will also be webcast live at www.gateway-conference.com, under the Presenting Companies tab.
To schedule a one-on-one meeting, visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to email@example.com or call Justin Vaicek at (949) 574-3860.
About the Gateway Conference
Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 emerging growth companies across a broad range of industries, from technology, business services and digital media, to clean-tech, consumer/retail, life sciences and natural resources. For more information, go to www.gateway-conference.com.
The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® (pterostilbene), which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.